|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,202,537
What is the scope and core claims of U.S. Patent 8,202,537?
U.S. Patent 8,202,537, granted on June 19, 2012, covers a method for treating cancer through the administration of an anti-CTLA-4 antibody. The patent primarily aims to protect the specific antibody composition, its method of use, and related therapeutic indications.
Key claims:
-
Claim 1: Describes a method of treating cancer in a human subject by administering an anti-CTLA-4 antibody. The claim specifies the antibody's characteristics, including that it is a human monoclonal antibody that binds to CTLA-4.
-
Claims 2-4: Narrow down to specifics about dosage regimens, including the amount (e.g., 3 mg/kg), administration frequency, and the treatment duration.
-
Claims 5-8: Cover the application of the antibody to specific cancers such as melanoma, non-small cell lung cancer, and renal cell carcinoma, emphasizing the broad therapeutic candidate scope.
-
Claims 9-12: Further specify the antibody's binding domains, such as an epitope on CTLA-4, and indicate that the antibody can be an antibody fragment or derivative.
The claim set delineates a process of administering an anti-CTLA-4 antibody with defined dosage, treatment schedule, and indications for various cancers, emphasizing both composition and use.
How broad is the patent's protection?
The patent's claims cover a broad class of human monoclonal antibodies targeting CTLA-4, specifically including:
- Any antibody binding to the CTLA-4 epitope as described.
- Methods involving specific dosing regimens.
- Indications for multiple types of cancer.
The scope encompasses various antibody formats, including fragments, implying a broad protective range against a range of anti-CTLA-4 therapies.
Compared to earlier patents, this patent emphasizes particular dosage regimens and cancer indications, which likely expand its enforceability across existing anti-CTLA-4 agents, notably ipilimumab.
What does the patent landscape for similar immunotherapy drugs look like?
Key patents and patents families:
| Patent Number |
Title |
Assignee |
Filing Date |
Grant Date |
Focus |
| US 8,202,537 |
Anti-CTLA-4 antibody treatment |
Bristol-Myers Squibb |
2004 |
2012 |
Method for treating cancer with anti-CTLA-4 antibody |
| US 7,679,377 |
Anti-CTLA-4 antibody constructs |
Medarex (now part of Bristol-Myers Squibb) |
2004 |
2009 |
Antibody design, binding domains, and uses |
| EP 2,063,091 |
Anti-CTLA-4 antibodies |
Medarex (reflected in European filings) |
2004 |
2010 |
Broad coverage on antibody constructs and uses |
Major players:
- Bristol-Myers Squibb: Holds patents related to ipilimumab (Yervoy), with patent families overlapping or extending the scope of US 8,202,537.
- Medarex: Developed foundational antibody technologies; their patents include specific binding domains and antibody formats.
- Bi-specifics and derivative patents: Emerging patent filings focus on bispecific antibodies targeting CTLA-4 and other immune checkpoints, extending patent scope.
Patent expiration considerations:
- The base patent (US 8,202,537) expires in June 2032, unless extended or challenged.
- Supplementary patents may cover manufacturing processes, specific antibody variants, or combination therapies with PD-1/PD-L1 inhibitors.
Competitive landscape:
- Multiple patents from Bristol-Myers Squibb guard the specific antibody sequences, dosing regimens, and combination indications.
- There is ongoing patent filament expansion regarding antibody formats, such as fragments, conjugates, and bispecifics targeting immune checkpoints, creating a dense landscape.
What are the implications for development and infringement?
- The patent’s broad claims on the method and composition imply that generic or biosimilar developers need to consider its scope when designing anti-CTLA-4 therapeutics.
- Claims covering specific dosing regimens could restrict alternative dosing strategies.
- Patent landscape shows strong patent protections by Bristol-Myers Squibb, requiring license agreements or design-around strategies for competitors.
Summary of key legal and strategic points:
- Claim breadth: Encompasses anti-CTLA-4 antibodies, dosing regimens, and indications, implying comprehensive protection.
- Patent landscape alignment: Multiple overlapping patents reinforce Bristol-Myers Squibb’s dominance in anti-CTLA-4 therapies.
- Expiration window: 2012–2032, with regulatory and IP strategies influencing market entry timelines.
- Freedom to operate: Limited without licensing, especially for antibody-based therapeutics targeting CTLA-4.
Key Takeaways
- U.S. Patent 8,202,537 claims a broad method for treating cancer with anti-CTLA-4 antibodies, including specific dosing and indications.
- Its scope covers various antibody formats targeting CTLA-4, substantial enough to impact the development of related therapeutics.
- The patent landscape involves multiple patents from Bristol-Myers Squibb and Medarex, primarily protecting the core anti-CTLA-4 antibody technology.
- Expiry is scheduled for June 2032, but ongoing patent applications could extend protection.
- Developers must navigate these patents carefully, with licensing or strategy adjustments needed for anti-CTLA-4-based drugs.
Frequently Asked Questions
1. Does patent 8,202,537 cover all anti-CTLA-4 antibodies?
No; it covers specific methods and compositions with certain characteristics, primarily focusing on particular dosing regimens and indications. Other anti-CTLA-4 antibodies may be protected by separate patents.
2. Can a new antibody targeting CTLA-4 avoid infringing this patent?
Potentially, if it employs different epitopes, formats, or dosing strategies not covered by the claims. Legal counsel is necessary to evaluate specific differences.
3. Are biosimilars affected by this patent?
Yes, biosimilars aiming to replicate the cited antibodies would need to license or design around the patent claims to avoid infringement.
4. What other patents might impact anti-CTLA-4 therapy development?
Patents on antibody formats, manufacturing processes, combination therapies, and specific indications from companies like BMS and Medarex.
5. When does this patent expire, and what are the options post-expiry?
Expires in June 2032. Post-expiry, generic or biosimilar versions can be developed without infringing, barring additional patents covering specific features.
References
- United States Patent and Trademark Office (USPTO). Patent 8,202,537.
- European Patent Office (EPO). EP 2,063,091.
- Bristol-Myers Squibb. Patent filings related to ipilimumab.
- Medarex. Patent filings covering anti-CTLA-4 antibody technology.
More… ↓
⤷ Start Trial
|
